# A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

> **NCT06261957** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 477 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Salbutamol HFA-134a
- **DRUG:** Salbutamol HFA-152a

## Key facts

- **NCT ID:** NCT06261957
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-31
- **Primary completion:** 2025-09-02
- **Final completion:** 2025-09-02
- **Target enrollment:** 477 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06261957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06261957, "A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06261957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*